Compare MPX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPX | PBYI |
|---|---|---|
| Founded | 1965 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.2M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | MPX | PBYI |
|---|---|---|
| Price | $8.17 | $6.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 43.7K | ★ 440.3K |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.93% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | 0.32 | ★ 0.74 |
| Revenue | ★ $244,419,000.00 | $211,995,000.00 |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $13.02 | N/A |
| P/E Ratio | $25.25 | ★ $9.24 |
| Revenue Growth | ★ 3.32 | N/A |
| 52 Week Low | $7.49 | $2.58 |
| 52 Week High | $10.08 | $7.29 |
| Indicator | MPX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 34.26 | 61.01 |
| Support Level | $9.23 | $6.76 |
| Resistance Level | $10.00 | $7.29 |
| Average True Range (ATR) | 0.40 | 0.33 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 5.05 | 64.88 |
Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. It operates in the powerboat manufacturing business segment in Nashville, Valdosta, and Georgia. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.